KOSDAQBiotech & Pharma489460

Biobijou

₩15,540▲ 3.60%2026-11-18 close
Market Cap
₩229.3B
Turnover
₩1.2B
Volume
80K
Shares out.
14.8M
PER
60.9×
PBR
3.7×
EPS
₩252
Dividend Yield
0.65%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

U.S. sales lift top line; margins are the test

Biobijou posted 3Q 2026 sales of KRW 13.4 billion, which the company says was its highest quarter since founding, but operating profit of KRW 2.5 billion rose only 2.0% year on year, so whether top-line growth carries into profit is the central question.

  1. 1

    3Q 2026 sales of KRW 13.4 billion rose 102.5% year on year, and the company said it was its highest quarterly sales since founding.

  2. 2

    The U.S. is now the core of overseas growth: U.S. sales reached KRW 14.33 billion in January–September 2026, up from KRW 7.06 billion in the first half, while China sales fell sharply in 3Q as new sales dropped.

  3. 3

    Profit has lagged sales: the operating margin fell from 31.1% in 2024 to 14.8% in 2025, and 3Q 2026 operating profit rose only 2.0% year on year.

  4. 4

    Net income attributable to owners swung to a loss of KRW 52.16 million in 3Q 2026, after a profit a year earlier.

  5. 5

    One customer accounted for 67.7% of 3Q consolidated sales, which raises customer concentration risk.

02

Business structure

Biobijou, founded in July 2018, is a medical aesthetics company that runs its own research lab and GMP manufacturing facilities to develop, produce and supply hyaluronic acid-based skin boosters and fillers, medical cosmetics and the extracellular matrix (ECM) skin reviser line.

Its filler Corena Premium and medical cosmetic brand CANDORLOV have secured domestic approval from Korea's Ministry of Food and Drug Safety, and the filler received its domestic product approval in March 2026.

The ECM skin reviser Cellibion, based on acellular allogeneic dermis (hADM), has been supplied to domestic dermatology clinics since late May 2026.

The product mix matters: in 3Q 2026, merchandise sales were KRW 12.35 billion, or 91.8% of consolidated sales, while sales of the company's own manufactured products fell 81.5% year on year to KRW 1.1 billion (MediCo Pharma news, November 16, 2026). Regional mix is shifting from China to the U.S.

China sales were KRW 20.0 billion in 2024 and KRW 19.38 billion in 2025, but new China sales fell sharply in 3Q 2026, while U.S. sales reached KRW 14.33 billion in January–September 2026. The company is widening U.S. distribution through Amazon, the Walmart online store, Ulta Beauty and pharmacy chains.

Customer concentration is high: a single customer generated KRW 9.11 billion, or 67.7%, of 3Q consolidated sales. The company competes in the same medical aesthetics market as domestic peers such as Hugel and PharmaResearch, and it operates local subsidiaries in the U.S., China and Vietnam.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.6B₩2.4B36.9%
2025Q4₩4B-₩2.7B−68.0%
2026Q1₩8B₩2.6B32.4%
2026Q2₩9.9B₩2.7B27.4%
2026Q3₩13.4B₩2.5B18.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩29.6B₩9.2B₩7.2B31.1%23.2%22.1%
2025₩28.5B₩4.2B₩4.2B14.8%6.7%2.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a reported basis, annual sales fell 3.9% year on year to KRW 28.5 billion in 2025 from KRW 29.6 billion in 2024. Operating profit dropped 54.2% to KRW 4.23 billion from KRW 9.23 billion, and the operating margin fell from 31.1% to 14.8%.

Net income attributable to owners fell 42.2% to KRW 4.15 billion from KRW 7.19 billion, while net income including non-controlling interests moved over the same period from KRW 7.19 billion to KRW 4.15 billion.

The company attributed the 2025 decline mainly to higher selling and administrative costs, including advertising for its new cosmetics business, and also pointed to more conservative accounting for receivables bad-debt rates and revenue recognition timing (Digital Today, March 2026).

Equity at end-2025 was KRW 62 billion, all attributable to owners, and total liabilities were KRW 1.77 billion, so the debt-to-equity ratio fell from 22.1% to 2.9%. Operating cash flow, however, turned from a KRW 558 million inflow in 2024 to a KRW 2.77 billion outflow in 2025.

The quarterly trend turned in 4Q 2025: sales fell 39.4% quarter on quarter to KRW 4.03 billion, and operating profit of KRW 2.45 billion in 3Q 2025 became an operating loss of KRW 2.74 billion in 4Q.

Sales then rose to KRW 8.01 billion in 1Q 2026 (up 99.0% quarter on quarter), KRW 9.88 billion in 2Q and KRW 13.4 billion in 3Q, with sales increasing for three consecutive quarters from 1Q 2026 through 3Q 2026.

Operating profit returned to KRW 2.59 billion in 1Q 2026, then reached KRW 2.7 billion in 2Q and KRW 2.5 billion in 3Q, the last of which rose only 2.0% year on year.

Net income attributable to owners turned positive at KRW 2.9 billion in 1Q 2026 and was KRW 2.54 billion in 2Q, then swung to a loss of KRW 52.16 million in 3Q against a KRW 2.44 billion profit a year earlier.

The company said cumulative sales through 3Q 2026 reached KRW 31.3 billion, already above full-year 2025 sales, but profit recovery has lagged sales growth. Net income attributable to owners over the last four quarters (4Q 2025 to 3Q 2026) totaled KRW 4.03 billion.

05

Industry analysis

Demand for skin boosters and fillers in Korea is driven by clinic-based aesthetic demand, and overseas distribution expansion now moves alongside it. Biobijou is growing its domestic clinic channel and its overseas online and offline channels at the same time.

The company described 2025 as a period of investment and distribution build-out, and framed 2026 as the year when North American channel expansion and new-product uptake would lift both sales and profitability (Asia Economy, September 2026).

It says it is targeting North America in line with rising global demand for K-beauty and aesthetics.

Its stated differentiators are its in-house research lab, GMP facilities and vertical integration from product planning through production and export, which independent research firm ARIS also cited as a competitive strength (August 2026 report).

For the ECM skin booster, ARIS reported that the company aims for a 5% share of the domestic market. The filler is under CE certification review in Europe after domestic approval, and the company expects certifications in China and Brazil.

Domestic listed medical aesthetics peers such as Hugel and PharmaResearch compete in the same market. In the U.S., the mix of online sales with pharmacy chains and pop-up stores is shaping how much sales can swing from quarter to quarter.

06

Outlook

The company expects overseas filler sales to rise sharply after it obtains overseas approvals in 2027, and it expects 2027 growth to exceed 2026 growth. Preparations for Cellibion's overseas launch are targeting entry in the first half of 2027 (Digital Today, November 16, 2026).

Expansion of filler sales regions depends on overseas approvals in 2027, and CE certification review in Europe is ongoing. For product expansion, ARIS reported that a chitosan-based skin booster called Dualin and a hydrated-type ECM product called Cellibion Y are in preparation (August 2026 report).

On production, the Hanam No. 1 plant has annual capacity of about 2.64 million units of skin boosters and fillers combined, and a planned second plant would add more than 6 million units, lifting total capacity above 8.64 million units, roughly 3.3 times the current level.

The timing and detailed schedule of that expansion should be read against what the company has disclosed so far. A Hana Securities analyst said in September 2026 that a turnaround is expected from diversifying sales across North America, the Middle East and Asia and from the launch of ECM products.

ARIS cited a market consensus of KRW 38.1 billion in 2026 sales, KRW 10.8 billion in operating profit and KRW 9.6 billion in net income, but that estimate predates the 3Q results and reflects its August 2026 reporting date. ARIS also reported that the company plans to buy back and cancel about KRW 2 billion of its own shares in 2026.

07

Valuation

PER
60.9×
PBR
3.7×
ROE
6.4%
EPS
₩252
BPS
₩4,151
Dividend per share
₩100

The current multiple is high relative to recent earnings, which means a large part of the valuation depends on expectations for profit recovery. Net income attributable to owners over the last four quarters totaled KRW 4.03 billion, and the 2025 operating margin of 14.8% was below the 2024 level.

Comparing today's multiples directly with the period when profits were stable is difficult. Price-to-book sits at a premium to net assets, and a debt-light balance sheet with equity fully attributable to owners underpins that premium.

The dividend yield is low and sits below the industry average, while a buyback and cancellation plan of about KRW 2 billion for 2026 has been presented as a shareholder return measure.

On market estimates, the ARIS consensus of KRW 10.8 billion in 2026 operating profit (August 2026 report) serves as the reference point for reading the current multiple. With cumulative operating profit through 3Q at KRW 7.8 billion, reaching that estimate would require a much larger profit in 4Q.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

U.S.-led overseas sales expansion

U.S. sales reached KRW 14.33 billion in January–September 2026, up from KRW 7.06 billion in the first half (MediCo Pharma, November 16, 2026).

Sales outside China and Korea totaled KRW 18.4 billion in the first nine months of 2026, or 58.8% of the total, roughly 15 times the prior-year level (Digital Today, November 16, 2026). CANDORLOV is expanding through Amazon and Walmart online, with pharmacy chains and pop-up stores added offline.

Consecutive quarterly sales growth

Sales rose from KRW 8.01 billion in 1Q 2026 to KRW 9.88 billion in 2Q and KRW 13.4 billion in 3Q, with sales increasing for three consecutive quarters from 1Q 2026 through 3Q 2026. The company said cumulative sales of KRW 31.3 billion through 3Q already exceeded full-year 2025 sales.

Press reports in August 2026 said 2Q results beat analyst consensus by 21% on sales and 35% on operating profit (MoneyToday, August 13, 2026).

Capacity expansion and vertical integration

The Hanam No. 1 plant has annual capacity of about 2.64 million units of skin boosters and fillers combined, and a completed second plant would lift total capacity above 8.64 million units, about 3.3 times the current level.

ARIS cited the in-house R&D, production and distribution network as a basis for lower costs and the ability to handle large orders (August 2026 report). The new ECM product Cellibion targets a 5% share of the domestic ECM skin booster market.

09

Bear factors

Thin margins despite sales growth

The operating margin fell from 31.1% in 2024 to 14.8% in 2025, and 3Q 2026 operating profit of KRW 2.5 billion rose only 2.0% year on year. That is small compared with the 102.5% increase in 3Q sales.

How the high merchandise share of 91.8% affects margins will show up in the operating margin trend in the next periodic report.

Customer concentration and shrinking own-product sales

One customer accounted for KRW 9.11 billion, or 67.7%, of 3Q 2026 consolidated sales (MediCo Pharma, November 16, 2026). The same report said sales of the company's own manufactured products fell 81.5% year on year to KRW 1.1 billion. High reliance on a single customer means order changes at that account can move quarterly results sharply.

Repeated swings into loss by quarter

In 4Q 2025 the company posted an operating loss of KRW 2.74 billion and a net loss attributable to owners of KRW 1.36 billion, and in 3Q 2026 it swung to a net loss attributable to owners of KRW 52.16 million. Operating cash flow turned into a KRW 2.77 billion outflow in 2025.

China sales were KRW 20.0 billion in 2024 and KRW 19.38 billion in 2025, and new China sales fell sharply in 3Q 2026.

10

Risk factors

Customer concentration risk

One customer generated 67.7% of 3Q 2026 consolidated sales (MediCo Pharma, November 16, 2026). A change in orders or contract terms with that account could move quarterly sales and operating profit sharply.

Because U.S. growth relies on online platforms and a small number of distributors, channel diversification should be tracked through the customer mix in coming quarters.

Overseas approval and regulatory risk

Overseas filler sales depend on CE certification in Europe and certifications in China and Brazil. The company expects overseas approvals in 2027, and if certification slips, the timing of higher overseas filler sales could slip as well.

Cellibion's overseas entry is also still in preparation for the first half of 2027, so results could diverge from expectations depending on schedule and approval outcomes.

Earnings volatility and accounting judgments

For 2025, the company cited higher selling and administrative costs, along with more conservative accounting for receivables bad-debt rates and revenue recognition timing (Digital Today, March 2026). Quarterly profit has swung widely, with a loss in 4Q 2025 and a net loss attributable to owners again in 3Q 2026.

Because earnings depend heavily on selling costs and accounting estimates, quarterly profit changes should be separated from sales growth.

11

What to watch next

  1. Late March 2027 (statutory deadline for the annual report)

    The 2026 annual report will confirm full-year sales and operating margin. The key items are 4Q profit relative to cumulative operating profit of KRW 7.8 billion through 3Q and the trend in net income attributable to owners.

  2. May 15, 2027 (statutory deadline for the Q1 quarterly report)

    Q1 2027 results will show whether U.S. sales hold up, how the merchandise share changes, and whether the operating margin recovers.

  3. First half of 2027

    Whether the overseas launch of the ECM skin reviser Cellibion begins. The company has framed this period as its preparation window.

  4. During 2027 (the company's planned year)

    Whether overseas filler approvals are obtained and how quickly sales regions expand. Progress on European CE certification is the key indicator.

  5. August 14, 2027 (statutory deadline for the Q2 quarterly report)

    Q2 2027 results will show whether customer concentration has eased and how the overseas sales share has moved.

12

Overall view

Biobijou reported 3Q 2026 sales of KRW 13.4 billion, its highest quarterly sales since founding, and cumulative sales through 3Q of KRW 31.3 billion already exceed full-year 2025 sales. Growth is centered on the U.S., where sales reached KRW 14.33 billion in January–September 2026.

On the other side, the 2025 operating margin fell to 14.8%, 3Q 2026 operating profit rose only 2.0% year on year, and net income attributable to owners swung to a loss of KRW 52.16 million. Customer concentration, with one customer at 67.7% of 3Q sales, and the decline in own-product sales are also facts to track.

Strengths include the in-house research and GMP facilities, the planned capacity expansion, and overseas plans for Cellibion and the filler. However, overseas approvals and new product launches fall on a 2027 timetable, so the timing of their impact on results is not yet set. The next checkpoints are the operating margin in the 2026 annual report and results for 1Q 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. view.asiae.co.kr
  2. etoday.co.kr
  3. medicopharma.co.kr
  4. supple.kr
  5. topdaily.kr
  6. m.etoday.co.kr
  7. view.asiae.co.kr
  8. view.asiae.co.kr
  9. supple.kr
  10. news.nate.com
  11. dealsite.co.kr
  12. supple.kr
  13. newstong.co.kr
  14. news.abbvie.com
  15. kr.investing.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis